Isothermal Nucleic Acid Amplification Technology Market Report and Forecast 2025-2034

Published Jul 28, 2025

Length 350 Pages

SKU # EMAR20319910

Description

The global isothermal nucleic acid amplification technology market size was valued at USD 4.56 Billion in 2024 , driven by the rising cases of pregnancy complications among women across the globe. The market size is anticipated to grow at a CAGR of 11.30% during the forecast period of 2025-2034 to achieve a value of USD 13.30 Billion by 2034 .

Isothermal Nucleic Acid Amplification Technology: Introduction

Isothermal amplification methods provide detection of a nucleic acid target sequence in a streamlined, exponential manner, and are not limited by the constraint of thermal cycling. Although these methods can vary considerably, they share some features in common.

Global Isothermal Nucleic Acid Amplification Technology Market Analysis

The key players are increasingly focusing on launching new products and kits, further propelling the market expansion. The increasing research and development activities are significantly aiding the isothermal nucleic acid amplification technology market growth.

According to a study, LAMP technology has been proven to be more effective in comparison with NAAT method as it can amplify target DNA rapidly and allows easy and fast detection of the target product. NAATs are routine laboratory techniques for the determination of disease agents. LAMP technology as a NAAT method allows for the amplification of target regions under isothermal conditions without the need for thermal cycling. It is a cost-effective method without the need for complicated instruments and high-cost laboratory infrastructure.

Global Isothermal Nucleic Acid Amplification Technology Market Segmentations
"Global Isothermal Nucleic Acid Amplification Technology Market Report and Forecast 2025-2034” offers a detailed analysis of the market based on the following segments:

Market Breakup by Technology

Helicase-dependent Amplification (HDA)
Nicking Enzyme Amplification Reaction (NEAR)
Loop-mediated Isothermal Amplification (LAMP)
Strand Displacement Amplification (SDA)
Nucleic Acid Sequence-based Amplification (NASBA)
Transcription Mediated Amplification (TMA)
Single Primer Isothermal Amplification (SPIA)
Other Technologies

Market Breakup by Products

Instruments
Reagent

Market Breakup by Target Type

Hospitals
Research Organization
Other End Users

Market Breakup by Region

North America
Europe
Asia Pacific
Latin America
Middle East and Africa

Global Isothermal Nucleic Acid Amplification Technology Market Overview

The market is witnessing significant growth driven by the rising prevalence of infectious diseases and cancer. The rising number of blood transfusion and donations, along with the increasing geriatric population across the globe, are some of the key factors which are propelling the growth of the market.

Increasing incidences of chronic diseases is also providing a crucial impetus to the market development. The rise in adoption of INAAT over PCR is due to the additional advantages it provides is further expected to propel the market growth. The high demand for low-cost and effective diagnostics procedures are also expected to add to the isothermal nucleic acid amplification technology market share. Isothermal technique is considered to be cost effective as it does not require to work on multiple temperatures and sample preparation, thus the demand for it has been rising.

North America is expected to lead the global market during the forecast period owing to the high incidence of chronic diseases. Continuous and effective technological advancement in isothermal nucleic acid amplification technology (INAAT) in the region has been propelling the market growth in the region. Moreover, the rising adoption of INAAT over conventional techniques in the region is also driving the global isothermal nucleic acid amplification technology market growth forward.

Isothermal Nucleic Acid Amplification Technology Market: Competitor Landscape

The key features of the market report include patent analysis, grants analysis, clinical trials analysis, funding and investment analysis, partnerships, and collaborations analysis by the leading key players. The major companies in the market are as follows:

Becton Dickinson and Company
Qiagen NV
bioMerieux
Abbot Laboratories
General ELectric
OptiGene Limited
Thermo Fisher Scientific
Genomtec
BioSystems
PCR Biosystems

*Please Note:* The report will take 5 business days to complete, after order confirmation.

1 Preface: 1.1 Objectives of the Study; 1.2 Key Assumptions; 1.3 Report Coverage – Key Segmentation and Scope; 1.4 Research Methodology
2 Executive Summary
3 Global Isothermal Nucleic Acid Amplification Technology Market Overview: 3.1 Global Isothermal Nucleic Acid Amplification Technology Market Historical Value (2018-2024); 3.2 Global Isothermal Nucleic Acid Amplification Technology Market Forecast Value (2025-2034)
4 Global Isothermal Nucleic Acid Amplification Technology Market Landscape: 4.1 Global Isothermal Nucleic Acid Amplification Technology: Developers Landscape; 4.1.1 Analysis by Year of Establishment; 4.1.2 Analysis by Company Size; 4.1.3 Analysis by Region; 4.2 Global Isothermal Nucleic Acid Amplification Technology: Product Landscape; 4.2.1 Analysis by Isotope; 4.2.2 Analysis by Technology; 4.2.3 Analysis by Applications
5 Global Isothermal Nucleic Acid Amplification Technology Market Dynamics: 5.1 Market Drivers and Constraints; 5.2 SWOT Analysis; 5.3 Porter’s Five Forces Model; 5.4 Key Demand Indicators; 5.5 Key Price Indicators; 5.6 Industry Events, Initiatives, and Trends; 5.7 Value Chain Analysis
6 Global Isothermal Nucleic Acid Amplification Technology Market Segmentation: 6.1 Global Isothermal Nucleic Acid Amplification Technology Market by Technology; 6.1.1 Market Overview; 6.1.2 Helicase-dependent Amplification (HDA); 6.1.3 Nicking Enzyme Amplification Reaction (NEAR); 6.1.4 Loop-mediated Isothermal Amplification (LAMP); 6.1.5 Strand Displacement Amplification (SDA); 6.1.6 Nucleic Acid Sequence-based Amplification (NASBA); 6.1.7 Transcription Mediated Amplification (TMA); 6.1.8 Single Primer Isothermal Amplification (SPIA); 6.1.9 Other Technologies; 6.2 Global Isothermal Nucleic Acid Amplification Technology Market by Products; 6.2.1 Market Overview; 6.2.2 Instruments; 6.2.3 Reagent; 6.3 Global Isothermal Nucleic Acid Amplification Technology Market by Target Type; 6.3.1 Market Overview; 6.3.2 Hospitals; 6.3.3 Research Organisation; 6.3.4 Other End Users; 6.4 Global Isothermal Nucleic Acid Amplification Technology Market by Region; 6.4.1 Market Overview; 6.4.2 North America; 6.4.3 Europe; 6.4.4 Asia Pacific; 6.4.5 Latin America; 6.4.6 Middle East and Africa
7 North America Isothermal Nucleic Acid Amplification Technology Market: 7.1 Market Share by Country; 7.2 United States of America; 7.3 Canada
8 Europe Isothermal Nucleic Acid Amplification Technology Market: 8.1 Market Share by Country; 8.2 United Kingdom; 8.3 Germany; 8.4 France; 8.5 Italy; 8.6 Others
9 Asia Pacific Isothermal Nucleic Acid Amplification Technology Market: 9.1 Market Share by Country; 9.2 China; 9.3 Japan; 9.4 India; 9.5 ASEAN; 9.6 Australia; 9.7 Others
10 Latin America l Isothermal Nucleic Acid Amplification Technology Market: 10.1 Market Share by Country; 10.2 Brazil; 10.3 Argentina; 10.4 Mexico; 10.5 Others
11 Middle East and Africa Isothermal Nucleic Acid Amplification Technology Market: 11.1 Market Share by Country; 11.2 Saudi Arabia; 11.3 United Arab Emirates; 11.4 Nigeria; 11.5 South Africa; 11.6 Others
12 Regulatory Framework: 12.1 Regulatory Overview; 12.1.1 US FDA; 12.1.2 EU EMA; 12.1.3 INDIA CDSCO; 12.1.4 JAPAN PMDA; 12.1.5 Others
13 Patent Analysis: 13.1 Analysis by Type of Patent; 13.2 Analysis by Publication year; 13.3 Analysis by Issuing Authority; 13.4 Analysis by Patent Age; 13.5 Analysis by CPC Analysis; 13.6 Analysis by Patent Valuation; 13.7 Analysis by Key Players
14 Grants Analysis: 14.1 Analysis by year; 14.2 Analysis by Amount Awarded; 14.3 Analysis by Issuing Authority; 14.4 Analysis by Grant Application; 14.5 Analysis by Funding Institute; 14.6 Analysis by NIH Departments; 14.7 Analysis by Recipient Organization
15 Clinical Trials Analysis: 15.1 Analysis by Trial Registration Year; 15.2 Analysis by Trial Status; 15.3 Analysis by Trial Phase; 15.4 Analysis by Therapeutic Area; 15.5 Analysis by Geography
16 Funding and Investment Analysis: 16.1 Analysis by Funding Instances; 16.2 Analysis by Type of Funding; 16.3 Analysis by Funding Amount; 16.4 Analysis by Leading Players; 16.5 Analysis by Leading Investors; 16.6 Analysis by Geography
17 Partnership and Collaborations Analysis: 17.1 Analysis by Partnership Instances; 17.2 Analysis by Type of Partnership; 17.3 Analysis by Leading Players; 17.4 Analysis by Geography
18 Supplier Landscape: 18.1 Becton Dickinson and Company; 18.1.1 Financial Analysis; 18.1.2 Product Portfolio; 18.1.3 Demographic Reach and Achievements; 18.1.4 Mergers and Acquisitions; 18.1.5 Certifications; 18.2 Qiagen NV; 18.2.1 Financial Analysis; 18.2.2 Product Portfolio; 18.2.3 Demographic Reach and Achievements; 18.2.4 Mergers and Acquisitions; 18.2.5 Certifications; 18.3 bioMerieux; 18.3.1 Financial Analysis; 18.3.2 Product Portfolio; 18.3.3 Demographic Reach and Achievements; 18.3.4 Mergers and Acquisitions; 18.3.5 Certifications; 18.4 Abbot Laboratories; 18.4.1 Financial Analysis; 18.4.2 Product Portfolio; 18.4.3 Demographic Reach and Achievements; 18.4.4 Mergers and Acquisitions; 18.4.5 Certifications; 18.5 General ELectric; 18.5.1 Financial Analysis; 18.5.2 Product Portfolio; 18.5.3 Demographic Reach and Achievements; 18.5.4 Mergers and Acquisitions; 18.5.5 Certifications; 18.6 OptiGene Limited; 18.6.1 Financial Analysis; 18.6.2 Product Portfolio; 18.6.3 Demographic Reach and Achievements; 18.6.4 Mergers and Acquisitions; 18.6.5 Certifications; 18.7 Thermo Fisher Scientific; 18.7.1 Financial Analysis; 18.7.2 Product Portfolio; 18.7.3 Demographic Reach and Achievements; 18.7.4 Mergers and Acquisitions; 18.7.5 Certifications; 18.8 Genomtec; 18.8.1 Financial Analysis; 18.8.2 Product Portfolio; 18.8.3 Demographic Reach and Achievements; 18.8.4 Mergers and Acquisitions; 18.8.5 Certifications; 18.9 BioSystems; 18.9.1 Financial Analysis; 18.9.2 Product Portfolio; 18.9.3 Demographic Reach and Achievements; 18.9.4 Mergers and Acquisitions; 18.9.5 Certifications; 18.10 PCR Biosystems; 18.10.1 Financial Analysis; 18.10.2 Product Portfolio; 18.10.3 Demographic Reach and Achievements; 18.10.4 Mergers and Acquisitions; 18.10.5 Certifications
19 Key Opinion Leaders (KOL) Insights (Additional Insight)
20 Company Competitiveness Analysis (Additional Insight): 20.1 Very Small Companies; 20.2 Small Companies; 20.3 Mid-Sized Companies; 20.4 Large Companies; 20.5 Very Large Companies
21 Payment Methods (Additional Insight): 21.1 Government Funded; 21.2 Private Insurance; 21.3 Out-of-Pocket

Pricing

Currency Rates

Single User Email from Publisher $4,949
Global Site License Email from Publisher $6,969

How Do Licenses Work?

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.

Chat Now